Company: EDSA
Filing Date: 2025-03-04
Form Type: S-3
Source: 0001171843-25-001239
Chunk: 12

Company: Edesa Biotech, Inc.
Filing Date: 2025-03-04
Form: S-3
Chunk 12
---
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
 of business of Stonepine Capital, LP is 919 NW Bond Street, Suite 204, Bend, OR 97703.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| (24) | Includes (i) 687,500 Shares purchased in the Private Placement and (ii) 93,750 Conversion Shares underlying the Preferred Shares purchased in the Private Placement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| (25) | David Rosen is the Managing Member of Rubric Capital Management GP LLC, the general partner                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
 of Rubric Capital Management LP, and has voting and investment control over the securities held by Rubric Capital Management LP.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| (26) | Includes (i) 687,500 Shares purchased in the Private Placement and (ii) 354,167 Conversion Shares underlying the Preferred Shares purchased in the Private Placement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| (27) | Kevin Kotler is the Managing Member of Broadfin Holdings, LLC and has voting and investment control over the securities held by Broadfin Holdings, LLC.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| (28) | Includes 182,291 Shares purchased in the Private Placement.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

Pursuant to the Investor Rights Agreement, so long as Velan Master, Velan Horizon and Velan Opp Fund II (collectively,
the “Lead Investors”) (i) beneficially own at least 51% of the Shares and Conversion Shares (calculated on an as-converted-to-common
shares basis, and subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization)
purchased by the Lead Investors at the closing and (ii) do not dispose of any Shares or Conversion Shares such that the Lead Investors
beneficially own less than 5% of the outstanding Common Shares of the Company, the Lead Investors will have the right to designate a director
nominee for election to our board of directors. David Liu, who is affiliated with the Lead Investors, was designated by the Lead Investors
to be appointed to the Company’s board of directors in accordance with the terms and conditions of the Investor Rights Agreement
on the Closing Date.

Additionally, the Investor
Rights Agreement includes certain protective provisions that restrict our ability to, among other things, (i) amend, modify, alter or
repeal any provision of our governing documents in a manner adverse to the holders of